The Lung Cough Syrup For The Treatment Of Chronic Brochitis Acute Payoxysm Period Of Clinical Research

Objective: to observe the lung cough syrup for chronic brochitis acute payoxysm (phlegmy heat syndromes lung yu the clinical curative effect of), and discusses the lung function mechanism of cough syrup, and provide scientific basis for clinical use.Methods: the choice of TCM and western medicine diagnosis accord with standard of chronic bronchitis acute onset of TCM syndrome type lung yu phlegmy heat diagnostic criteria of 80 cases by random cases, double-blind grouping method, divided into the treatment group and control group 40 cases in 40 cases. Using the lung in treatment group, and each treated cough syrup three times a day, 15ml, using powerful group, each for loquat 15ml, three times a day, a course for 14 days. Two groups of patients in the treatment of observation and the clinical symptoms, signs, chest X-ray and TNF alpha, c-reactive protein, TCM syndromes and to score points. Also watch adverse reactions.Results:1,and the total effective rate in treatment group and control group for 97.5%, 95%, two groups of comparisons, the statistical processing, two group (P> 0.05) differences.2,the clear lung cough syrup for chronic bronchitis patients with acute period before and after treatment were the main symptoms and signs significantly (P < 0.05), between the two groups, no statistically significant (P> 0.05).3,two groups of treatment and white blood count and chest X-ray without obvious changes (P> 0.05).4,two groups after treatment can reduce c-reactive protein and TNF alpha, compared with two groups before treatment, a statistically significant (P< 0.05), and the comparison between the two groups (P> 0.05), statistical analysis, two groups of similar effect.5,clinical trials, no obvious toxicity and adverse reaction.Conclusion:Clinical studies confirm the lung cough syrup can significantly improve chronic bronchitis acute episode phlegmy heat syndromes lung yu clinical symptoms, signs, TCM syndrome, chronic bronchitis patients can reduce serum TNF-a, c-reactive protein content, cough expectorant carambola, the heavily, efficacy, and safety.